Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Neurocrine Biosciences, Inc.    NBIX

NEUROCRINE BIOSCIENCES, INC. (NBIX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2018 10/12/2018 10/15/2018 10/16/2018 10/17/2018 Date
108.06(c) 111.48(c) 110.05(c) 114.29(c) 114.69 Last
1 332 273 692 646 462 463 662 742 446 532 Volume
+1.66% +3.16% -1.28% +3.85% +0.35% Change
More quotes
Financials (USD)
Sales 2018 451 M
EBIT 2018 31,6 M
Net income 2018 12,9 M
Finance 2018 487 M
Yield 2018 -
Sales 2019 667 M
EBIT 2019 199 M
Net income 2019 162 M
Finance 2019 582 M
Yield 2019 -
P/E ratio 2018 718,35
P/E ratio 2019 63,29
EV / Sales2018 21,3x
EV / Sales2019 14,2x
Capitalization 10 086 M
More Financials
Company
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company.It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders.The company product includes INGREZZA.Neurocrine Biosciences was founded by... 
More about the company
Surperformance© ratings of Neurocrine Biosciences, In
Trading Rating : Investor Rating :
More Ratings
Latest news on NEUROCRINE BIOSCIENCES, IN
10/17NEUROCRINE BIOSCIENCES : Announces Conference Call and Webcast of Third Quarter ..
AQ
10/15NEUROCRINE BIOSCIENCES : Announces Conference Call and Webcast of Third Quarter ..
PR
10/10ABBVIE : Receives Health Canada Approval of ORILISSA (elagolix) for the Treatmen..
AQ
10/09NEUROCRINE BIOSCIENCES : and Jnana Therapeutics Enter Strategic Collaboration to..
PR
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04NEUROCRINE BIOSCIENCES : to Present New Long-Term Data Analyses on INGREZZA at t..
AQ
10/01NEUROCRINE BIOSCIENCES : to Present New Long-Term Data Analyses on INGREZZA® (va..
PR
09/24NEUROCRINE BIOSCIENCES INC : Change in Directors or Principal Officers (form 8-K..
AQ
09/20BioTime Implements New Leadership Structure, Appoints Brian Culley as Chief E..
AQ
09/10NEUROCRINE BIOSCIENCES : to Present at the Morgan Stanley 16th Annual Global Hea..
AQ
More news
Sector news : Bio Therapeutic Drugs
10/16Sanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
09/28FDA Approves Libtayo to Treat Advanced Cutaneous Squamous Cell Carcinoma
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/16Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter.. 
10/15$NBIX Neurocrine Biosciences Announces Conference Call and Webcast of Third Q.. 
10/15New Research: Key Drivers of Growth for Neurocrine Biosciences, SS&C Tech.. 
10/13Analysts Expect Neurocrine Biosciences, Inc. $NBIX to Announce $0.44 EPS  
10/13Brokerages Expect Neurocrine Biosciences, Inc. $NBIX to Announce $0.44 EPS  
More tweets
Qtime:100
News from SeekingAlpha
10/09Neurocrine Bio teams up with Jnana Therapeutics in drug discovery 
10/06Health Canada OKs AbbVie's elagolix for endometriosis-related pain 
10/05NEUROCRINE : Time To Reduce? 
10/05The Biotech Conundrum 
09/20Premarket analyst action - healthcare 
Chart NEUROCRINE BIOSCIENCES, INC.
Duration : Period :
Neurocrine Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROCRINE BIOSCIENCES, IN
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 134 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Kevin Charles Gorman Chief Executive Officer & Director
William H. Rastetter Chairman
Matthew C. Abernethy Chief Financial Officer
Dimitri E. Grigoriadis Chief Research Officer
Bill Wilson Vice President-Information Technology & Operations
Sector and Competitors
1st jan.Capitalization (M$)
NEUROCRINE BIOSCIENCES, INC.41.84%10 086
GILEAD SCIENCES1.59%95 398
VERTEX PHARMACEUTICALS20.99%46 338
REGENERON PHARMACEUTICALS2.18%40 777
SAREPTA THERAPEUTICS INC136.05%8 671
GENMAB-11.78%8 632